Compounding pharmacies in California

By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified Sep 22, 2026

The California State Board of Pharmacy regulates compounding pharmacies in California. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

California at a glance

Pharmacy regulator: California State Board of Pharmacy
503A framework: Follows the federal 503A framework
Telehealth prescribing: Regulatory: Telehealth allowed
Asynchronous prescribing: Regulatory: Async allowed
Compounded GLP-1 access: Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving California

No verified compounding pharmacies serving California are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in California

The California State Board of Pharmacy regulates compounding under the Pharmacy Law (Business and Professions Code section 4000 and following) and Title 16 of the California Code of Regulations, sections 1735 (nonsterile) and 1736 (sterile) series, which the Board comprehensively rewrote in 2025 to align with USP chapters 795 and 797. California follows the federal 503A bulks framework for which substances may be compounded, but sets a stricter standard on copies: under 16 CCR 1735.1 and 1736.1 a compounded drug is essentially a copy of a commercially available product unless a change for an identified patient produces a clinically significant difference that the pharmacist verifies and documents, and the California rule does not treat a different strength or route alone as enough. Out-of-state pharmacies shipping into California must hold a nonresident pharmacy license under section 4112, and those shipping sterile compounded products (which includes injectable peptides) also need a nonresident sterile compounding license under section 4127.2. The Board's approved-regulations page lists the rewrite as one package (Compounded Drug Preparations: repeal and replacement of 16 CCR 1735 and following, new articles 1736, 1737, and 1738), adopted by the Board March 26, 2025, approved by the Office of Administrative Law June 19, 2025, and effective October 1, 2025; the page shows no separate earlier effective date for the essentially-a-copy provisions. [1] [2] [3] [4] [5] [7] [8] [10]

Compounded GLP-1 access in California

Branded Wegovy, Zepbound, Ozempic, and Mounjaro are available from California pharmacies, and California's asynchronous telehealth rules make branded prescriptions easy to obtain remotely. Compounded semaglutide and tirzepatide are more restricted in California than federal law alone requires: beyond the end of the FDA shortage allowances in 2025, California pharmacists must document a clinically significant difference for the individual patient before compounding a GLP-1 that matches a commercial product, and a lower price is not a qualifying reason. The Board's rules allow shortage-based compounding again only if the drug returns to the FDA or ASHP shortage list. [3] [6] [13]

Research use only sellers in California

California's Sherman Food, Drug, and Cosmetic Law bars selling, delivering, or giving away any new drug in California unless it has federal approval or a California approval (Health and Safety Code section 111550). "Research use only" peptides sold for human use are unapproved new drugs under both the Sherman Law and federal law, and only licensed pharmacies may dispense prescription drugs to California patients. [9] [14]

California notes on specific peptides

Semaglutide: Available branded by prescription, including after an asynchronous questionnaire-based telehealth exam under Business and Professions Code section 2242. Compounded semaglutide requires a documented clinically significant difference for the patient under California's 2025 essentially-a-copy rules, a stricter bar than the federal patient-specific exception. [3] [6] [13]
Tirzepatide: Available branded by prescription. Compounded tirzepatide faces the same California clinically significant difference requirement, and any compounded vial shipped from outside California must come from a pharmacy holding a nonresident sterile compounding license under section 4127.2. [3] [8]
BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. California pharmacies apply the federal bulks test plus the Board's rewritten compounding standards, and the Board has not issued a BPC-157 specific rule. [2] [11] [12]

How to check a compounding pharmacy in California

Search the California State Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration California requires before it ships to you. [1] [2] [3] [4] [5] [7] [8] [10]
Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in California. [9] [14]

Common questions in California

Why is compounded semaglutide harder to get in California than in other states?

California's 2025 compounding regulations treat a compounded drug as essentially a copy of a commercial product unless a change made for you produces a clinically significant difference that the pharmacist verifies and documents. That is stricter than the federal standard, and price is not a valid reason. [3] [13]

What licenses does an out-of-state pharmacy need to ship injectable peptides to California?

Two. It needs a nonresident pharmacy license under Business and Professions Code section 4112, and because injectable peptides are sterile compounded products it also needs a nonresident sterile compounding license under section 4127.2. Verify both on the Board of Pharmacy license lookup. [1] [7] [8]

Can a California pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [2] [11] [12]

All peptide legal questions for California